Karen focuses on therapeutic investments and coordinates the identification and evaluation of investment opportunities.
Karen serves on the board of Galecto, Xeltis, Vivet Therapeutics, AELIX Therapeutics and Minoryx Therapeutics. Formerly, she was board member at Cardoz and board member of Kala Pharmaceuticals.
When joining Ysios in 2008, Karen had over 10 years of experience in business development in various biotech and pharma companies.
At GLYCART in Zurich, Switzerland, she worked together with Ysios colleague Joël Jean-Mairet. After the sale of GLYCART to F. Hoffmann-La Roche in 2005, Karen was responsible for business development and alliance management for Roche in the areas of drug discovery technologies, preclinical oncology and viral diseases. After leaving Roche, she managed a consultancy firm providing advice and hands-on support to various biotechnology companies in business development and strategy, while supporting Ysios as a venture partner. Karen started her career as a consultant in McKinsey & Company’s Global Healthcare Practice.
Karen holds a master’s degree in Molecular Biology and a PhD in Cell Biology, both from the University of Konstanz, Germany.